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Hemodynamic-guided heart failure (HF) management
using pulmonary artery (PA) pressures reduces HF
hospitalizations (HFHs) in previously hospitalized HF
patients with New York Heart Association (NYHA) class
III symptoms. It remains uncertain whether this approach
reduces not only HFHs but all-cause mortality and if
benefits extend to patients with NYHA class II and IV HF
or to those symptomatic patients with elevated natriuret-
ic peptides without recent HFH.
Methods
GUIDE-HF is a prospective trial with 2 arms enrolling
patients with HF regardless of ejection fraction (EF). The
randomized arm is a single-blind, randomized, controlled
trial of PA pressure-guided therapy in NYHA class II-IV
patients (n = 1,000) with either a previous HFH orrom the aDivision of Cardiovascular Medicine, Vanderbilt University Medical Center,
ashville, TN, United States, bDivision of Cardiovascular Medicine, The Ohio State
niversity, Columbus, OH, United States, cCoronary Care Unit and Heart Failure
rogram, Veteran Affairs San Diego Healthcare, San Diego, CA, United States,
Division of Cardiology, Department of Medicine, RHJ Department of Veterans Affairs
edical Center and the Medical University of South Carolina, Charleston, SC, United
tates, eCardiovascular Center of Excellence, Department of Medicine, Division of
ardiology, Louisiana State University Health Sciences Center, New Orleans, LA,
nited States, fAdvocate Heart Institute, Naperville, IL, United States, gCenter for
dvanced Heart Disease, Cardiovascular Division, Brigham and Women's Hospital
nd Harvard Medical School, Boston, MA, United States, hDepartment of Medicine,
ontreal Heart Institute, Montreal, Quebec, Canada, iDepartment(s) of Psychology
nd Cardiovascular Sciences, East Carolina University, Greenville, NC, United States,
eart Function Program, Catawba Valley Cardiology, Conover, NC, United States,
nd kAbbott, Sylmar, CA, United States.
CT# NCT03387813
rants, contracts, or other forms of financial support: academic collaboration with the
onsor, Abbott, Sylmar, CA.
elationships with industry: Abbott, Sylmar, CA.
ubmitted October 18, 2018; accepted April 25, 2019.
eprint requests: JoAnn Lindenfeld, MD, Vanderbilt Heart and Vascular Institute,
edical Center East, 1215 21st Ave South, Suite #5209, Nashville, TN 37232.
-mail: joann.lindenfeld@vumc.org
002-8703
2019 The Authors. Published by Elsevier Inc. This is an open access article under the


























https://doi.org/10.1016/j.ahj.2019.04.014elevated natriuretic peptides (B-type natriuretic peptide/
NT-pro–B-type natriuretic peptide). All consenting sub-
jects will receive an implantable PA pressure sensor
(CardioMEMS HF System) followed by randomization to
either a treatment group, managed with provider remote
access to the hemodynamic data, or a control group,
managed without provider access to these data. Subjects
in the control group will receive scheduled, scripted,
sham contacts from the study team to maintain blinding
as to their study group assignment. The primary study end
point is the composite of cumulative HF events and all-
cause mortality at 12 months. Secondary end points
include quality-of-life and functional assessments. The
single arm of the trial is an observational arm in which
NYHA class III patients (n = 2,600) with either a previous
HFH or elevated natriuretic peptides (but no recent HFH)
will be implanted with a PA pressure sensor and observed
for occurrence of the primary composite end point of
cumulative HF events and mortality at 12 months. This
arm will test the hypothesis that hemodynamic-guided
care is similarly effective in HF patients enrolled on the
basis of elevated natriuretic peptide levels but no recent
HFH and those with a recent HFH.
Conclusions
GUIDE-HF is the largest clinical trial of hemodynamic-
guided HF management across a broad population of HF
patients, with a study design and sample size adequate to
examine survival, cumulative HF events, quality of life,
and functional capacity.
Hemodynamic-guided heart failure (HF) management
using remote, longitudinal assessment of pulmonary
artery (PA) pressures recorded by a permanently
implanted sensor is a novel means to maintain clinical
stability in patients with symptomatic HF syndromes.1-6
In several clinical trials using different implantable
devices, changes in PA pressure have been shown to
anticipate HF events. The degree of elevation in PA
pressures is also directly related to the risk of HF
events and mortality.7,8 Targeted efforts to reduce PA
pressures are associated with incrementally lower rates of
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(HFHs) in the presence of guideline-directed medical
therapy.4,7-9 The degree of reduction in PA pressure is
correlated with improved survival in patients with HF.9
These data support the hypothesis that hemodynamic-
guided HF management may improve survival compared
to traditional methods of outpatient care.
The CardioMEMS HF System (Abbott, Atlanta, GA)
consists of a wireless sensor implanted within the PA and
powered by an external interrogation device to provide
real-time transmission of PA pressure data from ambulatory
patients outside the HF clinic to a secure Web site for
provider review to guide decision making regarding HF
management. On the basis of the CHAMPION Trial, which
demonstrated that active HF management guided by
remotely obtained PA pressures using the CardioMEMS
HF System in patients with New York Heart Association
(NYHA) class III HF symptoms and history of a HFH in the
previous 12 months reduced subsequent occurrence of
HFHs,1,2 the Food and Drug Administration (FDA) ap-
proved use of the PA pressure sensor to guide HF
management in May 2014. In that study, incremental
reductions in the PA pressures in the monitored arm were
associated with both reduction in the frequency of HFH
and improvements in health-related quality of life among
patients with both preserved (HFpEF) and reduced
ejection fraction (HFrEF).3,4 Additionally, hemodynamic-
guided HF management in the subset of HFrEF patients
treated with guideline-directed medical therapy (GDMT)
was associated with a strong trend toward improved
survival compared to traditional clinical management.4,7
Consistent benefit is demonstrated in several retrospective
studies from the CHAMPION Trial.10-13 as well as extensive
analysis of “real-world” experience.6,14 and in Medicare
claims data managed in a commercial setting.5,15 Whether
the benefits of PApressure guided therapy can be extended
to a broader pool of patients withmilder (NYHA class II) or
more severe (NYHA class IV) HF or to thosewithout recent
hospitalization for HF but with elevation in natriuretic
peptide levels remains unclear. In addition, the potential
favorable impact of PA sensor-guided HF management on
mortality in patientswithNYHA class II-IVHF remains to be
definitively established.
The GUIDE-HF trial is designed to address these
current knowledge gaps and test the hypothesis that
medical intervention intended to lower PA pressures
and maintain hemodynamic stability will improve
mortality and HFH in patients with NYHA class II-IV
symptoms at persistently high risk for poor outcome
through a history of previous HFH or elevated natri-
uretic peptide. In this manuscript, we outline the
rationale and design of the GUIDE-HF clinical trial
program, which was recently approved as an investi-
gational device exemption trial by the US FDA and
the Centers for Medicare and Medicaid Services
(clinicaltrials.gov, NCT03387813).Methods
Trial strategy
The GUIDE-HF Trial consists of 2 component arms (a
single-blinded randomized arm and an observational
single arm) intended to examine complementary hypoth-
eses (Figure 1). It is funded by Abbott and will be
conducted at 140 centers in North America, including the
United States and Canada. This 2-arm design was driven
by practical considerations related to differential com-
mercial access to the PA pressure sensor by region in the
period following FDA approval for use in 2014. Some
geographic areas of the United States have received a
positive coverage decision from the assigned Medicare
Administrative Contractor for active HF management
using the CardioMEMS HF System in patients with NYHA
class III HF symptoms and history of a HFH in the
previous 12 months, whereas others have not. Medicare
patients meeting these criteria in Medicare Administrative
Contractor coverage regions will be enrolled in the single
arm unless the patient and physician chose the random-
ized arm of the trial. The single arm is designed to provide
a pathway for inclusion of NYHA class III patients with a
previous HFH meeting the currently labeled indication to
determine if the benefits in these patients are matched by
those NYHA class III patients who meet natriuretic
peptide criteria for enrollment but have not had an HFH.
In the randomized arm, NYHA class II-IV HF patients
(N = 1,000) with an HFH in the past 12 months or
elevated natriuretic peptide levels in the previous
30 days, regardless of left ventricular EF, will be
randomized in single-blind fashion to either treatment
(remotely obtained hemodynamic information to guide
management) or control group in 1:1 allocation. To mask
patient study group assignment among those assigned to the
control group, scripted sham calls will be made by the study
team to balance the number of subject contacts between the
treatment and control groups. The primary end point of the
randomizedarm is thecompositeof cumulativeHFevents and
mortality at 12 months. As per the recent FDAguidance,16 HF
events are defined to include both urgent HF visits (including
emergency department or hospital outpatient observation
unit visits) requiring intravenous diuretic therapy and HFHs.
Secondary end points will assess both quality of life (Kansas
City Cardiomyopathy Questionnaire [KCCQ-12] and EuroQol
5-Dimension, 5-LevelQuestionnaire [EQ-5D-5L]) and function-
al status (6-minute hall walk [6MHW] test).
The observational single arm will include HF patients
with NYHA class III symptoms who also have either a
previous HFH within 12 months prior to enrollment or
elevated natriuretic peptide levels without prior HFH in
12 months (same thresholds as the randomized arm)
within 30 days prior to enrollment. The single arm will
test the hypothesis that hemodynamic-guided care is
similarly effective in HF patients enrolled based on
elevated natriuretic peptide levels as in those with a
Figure 1
GUIDE-HF trial schematic.
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include cumulative HF event rates in the 12 months
postimplant compared to event rates in the 12 months
prior to implant.
All subjects involved in the randomized arm or the
single arm portion of this investigational device exemp-
tion trial who provide informed consent and volunteer
for the study will be screened for eligibility. The study
will be conducted in accordance with ICH standards on
Good Clinical Practice, and the study protocol will be
reviewed and approved at each participating site by the
appropriate Institutional Review Board prior to enroll-
ment of study patients. All events contributing to the
primary end point for either study arm, as well as allreportable adverse events, will be adjudicated by a
Clinical Events Committee. The randomized arm will be
monitored to ensure adequate enrollment of female
subjects as well as enrollment according to NYHA class.
Randomized arm
The randomized, control arm will be single-blind, as
subjects will not be aware of their randomized group
status. The trial will enroll 1,000 eligible subjects with
NYHA class II-IV symptoms and a previous HFH in the
prior 12 months or elevated circulating natriuretic
peptide levels (B-type natriuretic peptide [BNP] or N-
terminal pro-BNP [NT-proBNP], according to thresholds
defined Table I) in the prior 30 days. All consenting
Table I. Inclusion and exclusion criteria
Inclusion criteria
Diagnosis and treatment for HF (regardless of LVEF) for N90 d prior to the date of consent, and on stable, optimally-titrated GDMT for at least 30 d
Randomized arm only: NYHA class II, III, or IV HF symptoms documented within 30 d prior to consent.
Single arm only: NYHA class III HF symptoms documented within 30 d prior to consent.
HFH within 12 m prior to consent and/or elevated NT-proBNP (or BNP) within 30 d prior to consent defined as:
• Subjects with LVEF ≤40%: NT-proBNP ≥1000 pg/mL (or BNP 250 pg/mL)
• Subjects with LVEF N40%: NT-proBNP ≥700 pg/mL (or BNP ≥175 pg/mL)
• Thresholds for NT-proBNP/BNP corrected for BMI using a 4% reduction per BMI unit over 25 kg/m2
Subjects ≥18 y of age able and willing to provide informed consent
Chest circumference of b65 in if BMI is ≥35 kg/m2
Willing and able to upload PA pressure information and comply with the follow-up requirements
Exclusion criteria
Intolerance to all neurohormonal antagonists (ie, intolerance to ACE-I, ARB, ARNi, hydralazine/isosorbide dinitrate, and β-blockers)
ACC/AHA stage D refractory HF (including having received or currently receiving pharmacologic circulatory support with inotropes)
Received or are likely to receive an advanced therapy (eg, mechanical circulatory support or cardiac transplant) in the next 12 m
NYHA class IV HF patients with: continuous or chronic use of scheduled intermittent inotropic therapy for HF and an INTERMACS level of ≤4, or persistence of
fluid overload with maximum (or dose equivalent) diuretic intervention
eGFR b 25 mL/min/1.73 m2 and nonresponsive to diuretic therapy, or receiving chronic dialysis
Inability to tolerate or receive dual antiplatelet therapy or anticoagulation therapy for 1 m postimplantation
Significant congenital heart disease that has not been repaired and would prevent implantation of the CardioMEMS PA Sensor
Implanted with mechanical right heart valve(s)
Unrepaired severe valvular disease
Pregnant or planning to become pregnant in the next 12 m
An active, ongoing infection, defined as being febrile, an elevated white blood cell count, on intravenous antibiotics, and/or positive cultures (blood, sputum
or urine).
History of current or recurrent (≥2 episodes within 5 y prior to consent) pulmonary emboli and/or deep vein thromboses
Major cardiovascular event (eg, unstable angina, myocardial infarction, percutaneous coronary intervention, open heart surgery, or stroke) within 90 d prior
to consent
Implanted with CRT-P or CRT-D for less than 90 d prior to consent
Enrollment into another trial with an active treatment arm
Anticipated life expectancy of b12 m
Any condition that, in the opinion of the Investigator, would not allow for utilization of the CardioMEMS HF System to manage the subject using information
gained from hemodynamic measurements to adjust medications, including the presence of unexpectedly severe pulmonary hypertension (eg,
transpulmonary gradient N15) at implant RHC, a history of noncompliance, or any condition that would preclude CardioMEMS PA Sensor implantation
BMI, Body mass index; ACE-I, angiotensin converting enzyme-inhibitors; ARB, angiotensin receptor blockers; ARNi, angiotensin-neprilysin inhibitors; ACC, American College of
Cardiology; AHA, American Heart Association; eGFR, estimated glomerular filtration rate; CRT-P, cardiac resynchronization therapy–pacemaker; CRT-D, cardiac resynchronization
therapy–defibrillator.
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sensor. Subject education will be defined by the protocol
for all subjects and caregivers, including how to use the
system to upload PA pressures from home daily, basic
troubleshooting tips, and what to expect with respect to
participation in a randomized trial along with planned
communications from the investigative site. Hemody-
namic data from the implant right heart catheterization
(RHC) will be used to develop an initial strategy for
subsequent medication changes for all subjects enrolled.
After successful implantation of the sensor, subjects will
be randomly assigned 1:1 to either a treatment group,
which will be managed based on investigator knowledge
of daily uploaded PA pressures, or a control group, which
will be managed with traditional standard-of-care clinical
tools because investigators will not have access to
uploaded PA pressures. All subjects will upload hemody-
namic information daily from home but will not be made
aware of their PA pressures or study group assignment.For subjects within the treatment group, a regular review
of hemodynamic information from the Web site will be
completed by study personnel unblinded to the treatment
group assignment for each subject, with input from study
investigators. Study flow is outlined in Figure 2 for both the
randomized and single arms. This review will evaluate
whether PA pressure measurements are within the goal
range for each subject and, if not, detailing the correspond-
ing action (eg,medication change) to achieve hemodynamic
goals. Decisions to changemedication based on PA pressure
information will be documented and recorded on the
applicable case report form (CRF). If a subject's PA pressure
measurements fall outside of the goal range and no action is
planned, reasons for nonaction will be documented. Any
non–PA pressure-based HF medication change for subjects
in either randomized group will also be documented, along
with the clinical motivation for the change.
Although investigative sites will only have access to PA
pressure information for subjects within the treatment
Figure 2
GUIDE-HF subject contact schematic.
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reflecting the subject adherence to the daily upload
process will be available for both control and treatment
subjects. Failure to upload data will generate a contact
from the investigative site to discover the reason and to
encourage adherence in both groups. Subjects will have
protocol mandated in-office clinical encounters at 6 and
12 months following randomization. The nature of all
other clinical contacts relating to HF management will
also be recorded, along with all medication changes.
After the 12-month visit is completed, PA pressure
readings for control group subjects will be available for
clinical management through the Merlin.net website
(Abbott, Atlanta, GA).
To ensure ongoing protection of subject blinding with
respect to treatment group assignment, several specific
measures will be taken including scripted, blinded, and
balanced interactions with subjects in both treatment
groups; restricted clinician access to hemodynamic
information and subject treatment group assignments;
and limiting of postimplant hemodynamic information
uploads to patient equipment without pressure values.
For balanced site and subject interaction and subject
blinding between control and treatment groups, sites will
be required to contact all subjects in both groups of the
randomized arm at least once in a 2-week interval for the
first 3 months and then monthly until study completion.
Such site-initiated contacts with subjects will include
discussion of any applicable medication changes, as wellas subject compliance with uploading hemodynamic
information from home. Although PA pressure informa-
tion will only be available to providers for treatment
group subjects, subject compliance with uploading will
be available for both treatment and control group
subjects to allow for meaningful discussions regarding
device use with the control group.
To further ensure that subjects remain unaware of their
study group assignment, each site will designate blinded
personnel responsible for any site-initiated subject
communication related to HF management. These
blinded personnel will not be aware of the subject
group assignments and will follow a protocol-directed
scripted contact worksheet to communicate any issues
regarding upload compliance or changes in therapy
without revealing the rationale behind such changes (eg,
elevated PA pressures). Any symptoms reported volun-
tarily by the subject to blinded personnel will be
documented, and a scripted response will be provided,
if applicable. A separate, unblinded member of the study
team will be assigned to remotely monitor hemodynamic
information and compliance in collaboration with the
investigator, complete the scripted contact worksheet
designated for direct subject contact, and transfer to the
responsible blinded individual. The subject contact
worksheet will include time and date of contact and
will be maintained in source documentation, along with
the appropriate information documented by unblinded
personnel.
Table II. Clinical considerations to direct hemodynamic-guided HF management
PA pressure goals
PA diastolic: 8-20 mm Hg PA mean: 10-25 mm Hg PA systolic: 15-35 mm Hg
Optimization phase
• Uptitrate loop diuretic or add oral thiazide diuretic if hemodynamic evidence for excessive intravascular volume is present.
• Uptitrate or add hydralazine-nitrates in African-American subjects if vascular resistance is elevated.
• Consider hydralazine-nitrates in non–African-American subjects if vascular resistance is elevated.
• Uptitrate or add ACE-I or ARB if systemic blood pressure is adequate.
• Consider changing angiotensin intervention to ARB/ARNi.
• Uptitrate or add β-blocker if pressures remain optimal over time.
• Uptitrate or add spironolactone if tolerated by renal function and potassium.
• Intensify or repeat HF education regarding diet, sodium restriction, etc.
• Optimize CRT, if implanted.
• Evaluate for sleep apnea or other secondary causes of pulmonary hypertension.
• If in atrial fibrillation, maximize rate control or consider more aggressive attempts at normal sinus rhythm.
• Consider exercise training or cardiac rehabilitation.
Maintenance phase
• Gently increase loop diuretic dosage or add oral thiazide diuretic for rises above baseline.
• Consider changing angiotensin intervention to ARB/ARNi.
• Uptitrate or add spironolactone if tolerated by renal function and potassium.
• Decreasing diuretic intervention should be considered if pressures persistently decline over time and pass the lower-bound threshold set for the
individual subject.
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site will be restricted to members of the study team.
Similar to subjects, treating clinicians and other site
personnel not participating in the trial will not have
access to PA pressure readings or device-related informa-
tion and will remain masked as to study group assignment
for each subject. This restriction limits the potential of
subject unblinding through personnel outside of the
study team.
If a subject is admitted to the hospital, subjects will be
encouraged to bring their home system (Patient Elec-
tronic Unit, Abbott, Atlanta, GA) with them and continue
uploading PA pressure measurements while hospitalized.
Outside of subject-uploaded pressure information, which
providers on the study team may only access through a
secured Web site without subject awareness, no other PA
pressure measurements will be performed using hospital
equipment to further protect the subject blinding.
Single arm
The investigational single arm in GUIDE-HF is a
prospective, unblinded arm enrolling 2,600 subjects
with NYHA class III HF symptoms with either an HFH
in the previous 12 months or elevated natriuretic
peptides (BNP or NT-proBNP, according to thresholds
defined in Table I) in the previous 30 days. The primary
end point is a composite of cumulative HF events, as
defined previously, and all-cause mortality at 12 months
following PA pressure monitor implantation.
Subjects in the single arm will upload hemodynamic
information daily and receive hemodynamic-guided HF
management according to the protocol (see “Hemody-namic-Guided Care Protocol” section below). These
subjects will be contacted according to clinical need
and in response to PA pressure trends, without a
protocol-required frequency of phone contact. Subjects
will have protocol-required clinical visits at 6 and
12 months following implant. Other clinical visits or
contacts will be at the judgment of the investigator
personnel. The reason for any HF medication change
relating to HF will also be recorded on the CRF.
Natriuretic peptide inclusion criteria
The natriuretic peptide thresholds for inclusion were
chosen based on previous clinical trials with the intent to
include patients with a significant event rate and were
adjusted for both left ventricular EF (LVEF) and obesity
(4% reduction for each BMI unit above 25 kg/m2).
Although multiple factors can influence natriuretic
peptide levels, the thresholds were adjusted only for
factors that have been shown to affect natriuretic peptide
levels without changing the overall risk of the patient
population. Both increased LVEF and increased BMI have
been shown to lower natriuretic peptide levels but
without a reduction in overall risk for future events,
therefore meriting threshold adjustment. Atrial fibrilla-
tion has been shown to increase natriuretic peptide levels
but with the increased levels reflecting overall increased
risk for subsequent events, therefore not meriting
adjustment.
Hemodynamic-guided care protocol
Prior to and following enrollment, investigators will be
encouraged to follow current GDMT for all subjects
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of appropriate agents and ensuring appropriate target
dosing according to American Heart Association/Ameri-
can College of Cardiology/Heart Failure Society of
America guidelines.
Investigators will be encouraged to carefully use RHC
data obtained at the time of sensor implant procedure as
well as PA pressure data from the sensor (for treatment
group subjects) to develop a strategy for subsequent
medication changes. Right atrial pressure, pulmonary
capillary wedge pressure, and transpulmonary gradient
measurements may help guide initial diuretic choices and
use of vasodilator therapies. Medication changes and the
associated rationale (eg, in response to PA pressure
information or in response to signs and symptoms) will
be documented in the CRF throughout the study for all
subjects. Specific interventions will be at the discretion of
the treating provider. Investigators will be asked to titrate
medical therapies to achieve PA pressure goal ranges as in
the CHAMPION trial—PA systolic: 15-35 mm Hg; PA
mean: 10-25 mm Hg; PA diastolic: 8-20 mm Hg (Table II).
The PA pressure goals and medication interventions are
applicable to both the treatment and control groups of
the randomized arm, as well as the single arm. However,
for subjects within the control group of the randomized
arm, only PA pressure information from the initial RHC
done at the time of the PA sensor implant or any
additional medically necessary RHCs during the trial will
be available to the investigators. Remotely uploaded PA
pressure information from the control group will be
blocked from investigator review. Therefore, other than
medication changes resulting from information from RHC
procedures, control group subjects will not have
pressure-based medication changes over time and should
be managed instead according to routine practice as
informed by published clinical guidelines.
For treatment group subjects within the randomized
arm and those in the single arm, PA pressures will be used
by unblinded treating providers to adjust medications to
first optimize PA pressures to the goal pressure range and
then maintain their stability over time. The protocol
suggested interventions to lower PA pressures to goal
ranges early after implant are shown in Table II Once
pressures are optimized and stable, a new optimal
pressure range for each subject may be established, and
investigators are encouraged to enter the “maintenance
phase” of hemodynamic-guided care. During this time,
investigators are instructed to identify the new PA
pressure goal and set ranges around the goal to define
when investigators should be notified of a pressure
excursion. Subjects whose pressures are out of the goal
range will be placed on an automated “patient of interest”
report through the Web-based information system to
prioritize review of subjects in whom medication
changes are likely needed. During the maintenance
phase, investigators are encouraged to continue usingautomated threshold notifications or reports automatical-
ly identifying subjects meriting review, due to pressures
outside of thresholds or lack of compliance, to streamline
pressure data review and make the workflow of
reviewing larger numbers of patients more efficient.
During the maintenance phase of hemodynamic-guided
care or if baseline pressures at implantation are within the
protocol recommended target range, subacute deviations
of pressures above or below the target baseline are
usually a reflection of changes in intravascular volume.
Typically, a 3– to 5–mm Hg persistent pressure change
(increase or decrease) over 2-3 days or a 5–mm Hg
change in a single day will be considered “actionable”
trends leading to intervention.
Statistical analysis plan
Randomized arm
The analysis population of the GUIDE-HF randomized
arm will include subjects enrolled, successfully implanted
with a PA pressure sensor, and randomized. Primary and
secondary end points will be evaluated and compared
between groups following 12 months of randomized
evaluation.
The primary end point of the randomized arm is a
composite of cumulative HF events and all-cause mortal-
ity at 12 months postimplantation comparing the treat-
ment versus control groups. All primary end point events
will be accounted for using the Andersen-Gill model with
robust sandwich estimate of variance to test the
hypothesis. The model will contain a single covariate
representing randomized group (treatment or control).
Simulations for sample size were conducted under a joint-
frailty model, with 1-sided hypothesis testing performed
using an Andersen-Gill model with robust variance
estimate. The sample size estimated to provide approx-
imately 80% power at the 2.5% significance level with
20,000 simulations is 1,000 successfully implanted and
randomized subjects (500 per treatment group).
Secondary effectiveness end points of the GUIDE-HF
Randomized Arm include cumulative HF events at
12 months postimplantation. Health status, as assessed
by the EQ-5D-5L and the KCCQ-12 questionnaires, along
with functional status assessed by the 6MHW test will be
evaluated at baseline and at 6 and 12 months postim-
plantation. In addition, the individual components of the
primary end point will each be evaluated as descriptive
secondary effectiveness end points.
Single arm
The primary end point of the single arm study is a
composite of cumulative HF events and all-cause mortal-
ity at 12 months postimplantation. Two subject groups
will be compared: (a) subjects having elevated NT-
proBNP (or BNP) but without having a HFH in the year
prior, who would not have been eligible for enrollment in
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prior but without elevated NT-proBNP (or BNP) who
would have been eligible for enrollment in CHAMPION.
The analysis population for the primary end point will
include subjects enrolled into the single arm with
successful sensor implantation and either elevated NT-
proBNP (or BNP) only or a recent HFH only. Subjects
with both elevated NT-proBNP (or BNP) and a recent
HFH will not be included in the analysis for the primary
end point. Hypotheses will be tested at the 5%
significance level for the single arm primary end point
at 12 months using a two, one-sided test (TOST)
procedure. To determine equivalence of the 2 groups,
the TOST procedure will be performed using a 2-sided
90% CI of the hazard ratio obtained from the Andersen-
Gill model using robust sandwich variance estimates with
a single covariate representing the 2 subject groups.
Primary end point sensitivity analyses will be run with the
following covariates in the Andersen-Gill model: subject
group, propensity quintile and interaction between
subject group, and propensity quintile to adjust for any
possible imbalances in covariates. Simulations for sample
size estimation were conducted under a joint-frailty
model, with TOST hypothesis testing conducted using
an Andersen-Gill model with robust variance estimate.
The sample size estimated to provide approximately 90%
power at the 5% significance level with 20,000 simula-
tions is 2,600 successfully implanted subjects (approxi-
mately 780 [30%] with a recent HFH only, 780 [30%] with
elevated NT-proBNP [or BNP] only, and 1,040 [40%] with
both a recent HFH and elevated NT-proBNP [or BNP]).
The secondary effectiveness end points of the single
arm study include cumulative HF events at 12 months
postimplantation and the annualized rate of recurrent
HFHs at 12 months post-implantation compared to the
annualized rate of recurrent HFHs in the 12 months prior
to implantation. In addition, the individual components
of the primary end point at 12 months postimplantation
will each be evaluated as descriptive secondary effective-
ness end points: HFHs, urgent HF visits for intravenous
diuretic therapy, and all-cause mortality. If the primary
end point for the single arm is met, the secondary
effectiveness end points will be evaluated hierarchically,
with cumulative HF events tested first followed by HFH as
12 months post- versus preimplantation. The analysis
population for the secondary effectiveness end points
will include subjects enrolled into the single arm and
successfully implanted, regardless of NT-proBNP (or BNP)
and HFH history unless otherwise noted.
Safety assessments
Both the randomized arm and single arm of the GUIDE-
HF trial will assess device or system-related complication
rates as secondary safety end points with comparison to
previous trials using the CardioMEMS HF System.1,2 All
reportable adverse events (eg, Serious Adverse Events,Adverse Device Effects, Serious Adverse Device Effects,
Unanticipated Adverse Device Effects, and non-Adverse
Event study device issues) identified during scheduled or
unscheduled visits will be reported, documented, and
adjudicated by the Clinical Events Committee. The
analysis population for the secondary safety end point
of both arms will include all subjects with an attempted
implant (intent to treat) but will be analyzed separately
for each arm.Discussion
The GUIDE-HF study program is designed to definitive-
ly assess the benefit of hemodynamic-guided HF manage-
ment in ambulatory patients across a broad symptomatic
range of symptom severity (NYHA class II-IV) and is
powered to determine whether preventing clinical
decompensation reduces cumulative HF events and
overall mortality. A key secondary hypothesis is that
hemodynamic monitoring will benefit the expanded
population of NYHA II-IV HF patients without a recent
HFH but with elevated natriuretic peptides equivalently
to those with NYHA III symptoms and a recent HFH who
are within the current FDA-labeled indication for
implantable hemodynamic monitoring.
Implantable hemodynamic monitoring has emerged as
an effective strategy for reducing HF events in patients
with NYHA class III HF symptoms and a prior HFH within
12 months. Despite FDA approval, widespread adoption
of this strategy has been limited by remaining gaps in
knowledge resulting from the CHAMPION trial indication
and design, as well as the lack of power in that study to
examine clinical end points beyond HFHs, including
cumulative HF events and mortality. Recent analysis has
suggested that both PA pressures and relative change of
PA pressures resulting from hemodynamic HF manage-
ment are independent predictors of mortality in HF
patients.4,8 However, the association of PA pressures
with mortality and potential to reduce mortality com-
bined with HF events in the HF population has yet to be
established in a clinical trial. It is also well known that
recurrent HFHs impair quality of life, contribute to HF
progression, and increase mortality risk.17 However,
recent data from the PARADIGM-HF trial have demon-
strated that any event requiring rescue diuretic therapy,
including both HFHs and urgent HF visits, is associated
with approximately 5 times higher risk of death.18 Lastly,
substantial evidence suggests that natriuretic peptide
levels in ambulatory patients may be a better way to
evaluate the presence of persistent congestion compared
to NYHA class or a previous hospitalization and may
improve efforts to reduce ongoing and recurrent
inpatient hospitalizations within health care.19 The
GUIDE-HF trial has several aims designed to address
remaining questions about the value of hemodynamic
monitoring in HF management. Key design features are
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August 2019the inclusion of a broader pool of patients across a wide
spectrum of HF symptom severity (NYHA class II-IV), the
option to include patients without prior HFH but with
elevated natriuretic peptide levels, and the analysis of
composite HF events, not merely HFHs. The primary end
point of cumulative HF events coupled with all-cause
mortality will examine whether maintenance of hemo-
dynamic stability fundamentally alters or reverses the
underlying disease progression characteristic of either
HFpEF or HFrEF. Furthermore, long-term patient-
reported outcomes using the KCCQ-12 and EQ-5D-5L
and functional status with the 6MHW test will examine
patients' life experiences when HF is a component of
their medical problem list and the associated impact of
hemodynamic stability on quality of life.
Summary
GUIDE-HF is designed specifically to definitively
address the impact of hemodynamic-guided HF manage-
ment within a broader HF patient population, particularly
with respect to patient outcomes as assessed by
cumulative HF events and all-cause mortality. Additional-
ly, the GUIDE-HF trial will evaluate whether the effects of
hemodynamic-guided on HF events are mirrored by
changes in longer-term quality of life and functional
capacity. The broad HF patient population, diversity of
outcome measures, and significant sample size of the
GUIDE-HF trial will uniquely enable the opportunity for
exploration into the potential disease-altering effects of
hemodynamic-guided HF management.
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